Evaluation of the Impact of the COVID-19 Pandemic on the Clinical Presentation of Pediatric Celiac Disease Authors: Edibe Gozde Basaran, Coskun Firat Ozkececi, Melike Arslan, Yasin Maruf Ergen, Necati Balamtekin Published: 2026 ABSTRACT PurposeTo evaluate the impact of the coronavirus disease (COVID-19) pandemic on the clinical presentation, serological load, and duodenal histopathological damage in pediatric celiac disease (CD) patients compared to the pre-pandemic period.MethodsThis retrospective cohort study included 114 pediatric patients with biopsy-confirmed CD diagnosed between June 2017 and November 2021. The study population was divided into a Pandemic Group (n=57) and a Pre-Pandemic Control Group (n=57). To ensure histopathological comparability, patients diagnosed without biopsy due to high antibody titers were excluded. Demographic data, clinical symptoms, anti-tissue transglutaminase antibody (anti-tTG) IgA/IgG titers, and Modified Marsh scores were analyzed.ResultsThe median age at diagnosis was significantly higher in the Pandemic Group compared to the Pre-Pandemic Group (p=0.004). Regarding serology, the proportion of patients with anti-tTG IgA levels ≥10 times the upper limit of normal (ULN) was significantly elevated in the Pandemic Group (75.4%) compared to the controls (47.4%) (p=0.011). A significant difference was also noted in anti-tTG IgG levels (p=0.032). However, no statistically significant differences were observed between the periods regarding clinical presentation phenotypes (p=0.084) or the severity of duodenal mucosal damage based on Modified Marsh scores (p=0.076).ConclusionThe COVID-19 pandemic resulted in a significant delay in diagnosis age and an increased serological load in pediatric CD cases. However, this increased load did not correspond to a significant worsening in duodenal mucosal damage. These results underscore the critical importance of maintaining diagnostic pathways for chronic conditions during health crises. INTRODUCTION In genetically predisposed pediatric populations, celiac disease (CD) manifests as a chronic autoimmune enteropathy triggered by dietary gluten that can result in a broad spectrum of clinical manifestations, ranging from failure to thrive to severe malabsorption [12]. Elevated anti-tissue transglutaminase antibody (anti-tTG) levels—specifically anti-tTG immunoglobulin A (IgA) or anti-tTG immunoglobulin G (IgG) in individuals with IgA deficiency—are widely used for both the diagnosis of CD and the assessment of adherence to a gluten-free diet. Higher anti-tTG titers have been shown to correlate with greater severity of duodenal mucosal injury, particularly at markedly elevated levels [3]. The abrupt onset of the coronavirus disease 2019 (COVID-19) pandemic placed unprecedented strain on healthcare systems worldwide. Reduced outpatient visits and delays in referral pathways adversely affected healthcare-seeking behavior and prolonged the diagnostic process [45]. In addition, the postponement of elective invasive procedures, including upper gastrointestinal endoscopy, further hindered the timely diagnosis of CD [67]. Although several studies have reported delays in CD diagnosis during the pandemic, the impact of these delays on serological burden and histopathological severity in children remains poorly understood. This study aimed to evaluate the impact of pandemic-related diagnostic delays on pediatric CD by comparing patients diagnosed during the pandemic with those diagnosed before the pandemic. Specifically, we assessed differences in clinical presentation, anti-tTG IgA titers, and the severity of duodenal mucosal injury, as determined by the Modified Marsh classification. MATERIALS AND METHODS Study design and data collection This retrospective cohort study included pediatric patients diagnosed with CD and followed at the Pediatric Gastroenterology Clinic of Gülhane Training and Research Hospital between June 2017 and November 2021. Study data were collected in 2022 through a retrospective review of the hospital information management system and patients' medical records. Demographic characteristics, presenting symptoms, serum total IgA levels, CD-specific serologic test results (anti-tTG IgA and IgG), and histopathological findings were extracted using standardized data collection forms developed for the study. Study population and inclusion criteria The study population comprised patients aged 1–18 years who were diagnosed with CD according to the diagnostic criteria established by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) during the study period [89]. Because the study spanned 2017–2021, diagnoses were made according to either the 2012 or the 2020 ESPGHAN guidelines, depending on the date of diagnosis [89]. Although the 2020 ESPGHAN guidelines permit a diagnosis without duodenal biopsy in patients with anti-tTG IgA levels ≥10× the upper limit of normal (ULN), one of the primary objectives of this study was to assess the impact of the COVID-19 pandemic on the severity of duodenal tissue damage. Therefore, histopathological confirmation was considered essential for study inclusion [910], and patients without histopathological examination were excluded. Accordingly, the study population was stratified into two groups: the Pandemic Group, comprising 57 patients diagnosed during the COVID-19 pandemic, and the Pre-Pandemic Group, comprising 57 patients diagnosed before the pandemic. During the pandemic period, 61 patient records were initially reviewed. Four patients diagnosed using the no-biopsy approach based on anti-tTG IgA levels ≥10×ULN were excluded because histopathological data were unavailable for comparison. Clinical evaluation Clinical presentation was classified according to the Oslo Consensus definitions into three subgroups [11]: • Classic CD: Characterized by signs and symptoms of malabsorption, including diarrhea, steatorrhea, weight loss, and growth failure. • Classic CD: Characterized by signs and symptoms of malabsorption, including diarrhea, steatorrhea, weight loss, and growth failure. • Non-classic CD: Characterized predominantly by extraintestinal manifestations, such as constipation, abdominal bloating, abdominal pain, anemia, short stature, and dermatitis herpetiformis. • Non-classic CD: Characterized predominantly by extraintestinal manifestations, such as constipation, abdominal bloating, abdominal pain, anemia, short stature, and dermatitis herpetiformis. • Subclinical CD: Defined as asymptomatic disease identified by serologic screening and confirmed histopathologically in individuals belonging to at-risk groups. • Subclinical CD: Defined as asymptomatic disease identified by serologic screening and confirmed histopathologically in individuals belonging to at-risk groups. Serologic evaluation CD serologic screening was performed using anti-tTG IgA and IgG antibodies [8]. Antibody concentrations were measured using enzyme-linked immunosorbent assay (Orgentec, Mainz, Germany). In patients with selective IgA deficiency, defined as age-adjusted low serum total IgA levels, anti-tTG IgG results were used for serologic assessment. To evaluate serologic severity, antibody titers were categorized according to multiples of the assay-specific ULN as follows: negative, <3×ULN, 3–<5×ULN, 5–<7×ULN, 7–<10×ULN, and ≥10×ULN. Endoscopic and histopathological evaluation All included patients underwent upper gastrointestinal endoscopy as part of the diagnostic evaluation. During the procedure, at least two biopsy specimens were obtained from the duodenal bulb and at least four from the distal duodenum, in accordance with ESPGHAN recommendations [8]. Histopathological findings were retrospectively retrieved from pathology reports and classified according to the modified Marsh classification (Types 2, 3a, 3b, and 3c) [910]. The results were recorded in the standardized study database. Ethical approval The study protocol was approved by the Ethics Committee of the University of Health Sciences Gülhane Scientific Research (Decision No. 2022-35; Approval no. 46418926). All study procedures were conducted in accordance with the ethical principles of the Declaration of Helsinki. This study was a retrospective study that did not cause any harm to the study subjects; therefore, the requirement of informed consent was waived by the board. Statistical analysis Statistical analyses were performed using the IBM SPSS Statistics for Windows, Version 26.0 (IBM Co.). The normality of continuous variables was assessed using the Kolmogorov–Smirnov test. Normally distributed data are presented as mean±standard deviation, whereas non-normally distributed data are presented as median (minimum–maximum). Between-group comparisons were performed using the independent-samples t-test for normally distributed variables and the Mann–Whitney U-test for non-normally distributed variables. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test, as appropriate. All statistical tests were two-sided, and a p-value<0.05 was considered statistically significant. RESULTS A total of 114 biopsy-confirmed CD cases were included in the study, with equal numbers assigned to the Pandemic Group (n=57) and the Pre-Pandemic Control Group (n=57) (Table 1). Four patients diagnosed during the pandemic according to the current ESPGHAN guidelines without undergoing duodenal biopsy because their anti-tTG IgA levels were ≥10×ULN were excluded due to the absence of histopathological data. Table 1Comparison of demographic and anthropometric characteristics of pediatric patients diagnosed with celiac disease before and during the coronavirus disease pandemicCharacteristicPre-Pandemic Group (n=57)Pandemic Group (n=57) p-valueAge at diagnosis (yr)7 (1–14)10 (2–17)0.004* Weight SDS−1.3 (−3.5 to 2.0)−1.06 (−2.95 to 2.06)0.351* Height SDS−1.13 (−2.3 to 0.57)−0.88 (−5.18 to 1.89)0.154* BMI SDS−0.79 (−3.70 to 2.44)−0.61 (−3.50 to 2.1)0.377* Sex0.420** Female37 (64.9)41 (71.9)Male20 (35.1)16 (28.1)Nutritional status0.518** Normal31 (54.4)35 (61.4)Mild malnutrition20 (35.1)15 (26.3)Moderate malnutrition2 (3.5)5 (8.8)Severe malnutrition1 (1.8)1 (1.8)Overweight3 (5.3)1 (1.8)Obese0 (0.0)0 (0.0)Values are presented as median (range) or number (%).BMI: body mass index, SDS: standard deviationscore.*Mann–Whitney U-test, **Chi-square test (Fisher’s exact test). Comparison of demographic and anthropometric characteristics of pediatric patients diagnosed with celiac disease before and during the coronavirus disease pandemic Values are presented as median (range) or number (%). BMI: body mass index, SDS: standard deviationscore. *Mann–Whitney U-test, **Chi-square test (Fisher’s exact test). Compared with the Pre-Pandemic Control Group, patients in the Pandemic Group had a significantly higher median age at diagnosis (10 vs. 7 years, p=0.004). No significant between-group differences were observed in weight standard deviation score (SDS), height SDS, body mass index (BMI) SDS, sex distribution, or nutritional status at outpatient presentation (all p>0.05; malnutrition status: p=0.518) (Table 1). The distribution of clinical presentations in the Pre-Pandemic Control Group was 70.2% classic, 19.3% non-classic, and 10.5% subclinical CD. The corresponding proportions in the Pandemic Group were 50.9%, 36.8%, and 12.3%, respectively. Although the Pandemic Group showed a trend toward a higher proportion of non-classic presentations and a lower proportion of classic presentations, the overall distribution of clinical presentations did not differ significantly between the groups (p=0.084) (Table 2). Table 2Comparison of clinical presentation, serological titers, and histopathological stages between the groupsCharacteristicPre-Pandemic Group (n=57)Pandemic Group (n=57) p-valueClinical presentation0.084* Classic40 (70.2)29 (50.9)Non-classic11 (19.3)21 (36.8)Subclinical6 (10.5)7 (12.3)Anti-tTG IgA level0.011* Negative4 (7.0)2 (3.5)<3×ULN7 (12.3)3 (5.3)3≤5×ULN3 (5.3)6 (10.5)5≤7×ULN8 (14.0)1 (1.8)7≤10×ULN8 (14.0)2 (3.5)≥10×ULN27 (47.4)43 (75.4)Anti-tTG IgG level(n=28)(n=40)0.032* Negative2 (7.1)8 (20.0)<3×ULN9 (32.1)10 (25.0)3≤5×ULN7 (25.0)5 (12.5)5≤7×ULN3 (10.7)4 (10.0)7≤10×ULN7 (25.0)4 (10.0)≥10×ULN0 (0.0)9 (22.5)Modified marsh score0.076* Type 25 (8.8)4 (7.0)Type 3a7 (12.3)13 (22.8)Type 3b21 (36.8)29 (50.9)Type 3c24 (42.1)11 (19.3)Values are presented as number (%).Anti-tTG: anti-tissue transglutaminase antibody, ULN: upper limit of normal.*Chi-square test (Fisher’s exact test). Comparison of clinical presentation, serological titers, and histopathological stages between the groups Values are presented as number (%). Anti-tTG: anti-tissue transglutaminase antibody, ULN: upper limit of normal. *Chi-square test (Fisher’s exact test). Patients were further stratified according to anti-tTG IgA and IgG titers. The proportion of patients with anti-tTG IgA levels ≥10×ULN was significantly higher in the Pandemic Group than in the Pre-Pandemic Control Group (75.4% vs. 47.4%, p=0.011). No cases of selective IgA deficiency were identified in either group. The distribution of anti-tTG IgG titers also differed significantly between the groups (p=0.032) (Table 2). Duodenal mucosal damage was assessed using the Modified Marsh classification. In the Pre-Pandemic Control Group, the proportions of patients with Modified Marsh types 2, 3a, 3b, and 3c lesions were 8.8%, 12.3%, 36.8%, and 42.1%, respectively. In the Pandemic Group, the corresponding proportions were 7.0%, 22.8%, 50.9%, and 19.3%, respectively. Although the Pandemic Group exhibited a higher frequency of Modified Marsh type 3b lesions and a lower frequency of advanced mucosal damage (Modified Marsh type 3c), the overall distribution of histopathological findings did not differ significantly between the groups (p=0.076) (Table 2). DISCUSSION This study demonstrated that, among pediatric patients with CD diagnosed during the COVID-19 pandemic, the median age at diagnosis and the CD-specific serological burden, particularly the proportion of patients with anti-tTG IgA levels ≥10×ULN, were significantly higher than in the pre-pandemic period. Despite this marked increase in serological activity, the severity of duodenal mucosal injury, as assessed by the Modified Marsh classification, did not differ significantly between the two periods. Restrictions on elective medical services during the pandemic, together with families' reluctance to seek medical care because of concerns about severe acute respiratory syndrome coronavirus 2 infection, contributed to delays in the diagnosis of CD, as observed for many other chronic diseases [61213]. In addition, invasive procedures, including upper gastrointestinal endoscopy, were temporarily restricted. International professional societies, including NASPGHAN and ESPGHAN, recommended postponing non-urgent endoscopic procedures to reduce the risk of viral transmission and preserve personal protective equipment [14]. Similarly, in our country, directives issued by the Ministry of Health led many centers to temporarily suspend elective endoscopic procedures, limiting endoscopy to patients with urgent indications, such as gastrointestinal bleeding or foreign body ingestion [7]. A notable finding of our study was the marked increase in the proportion of patients diagnosed during the pandemic with very high anti-tTG IgA titers (≥10×ULN), which rose from 47.4% before the pandemic to 75.4% during the pandemic (p=0.011). The significantly older age at diagnosis and higher anti-tTG IgA titers observed in the pandemic group likely reflect delays in diagnosis. Previous studies have demonstrated a positive association between prolonged gluten exposure and increased serological antibody titers in CD [315]. Accordingly, the elevated serological burden observed during the pandemic may be attributable to continued gluten exposure resulting from delayed diagnosis, leading to sustained immune activation within the intestinal mucosa. Despite the significantly greater serological burden, no significant difference was observed in the severity of histopathological damage between the pandemic and pre-pandemic groups (p=0.076). Similarly, Çakır et al. [16] reported no differences in histopathological stage between the two periods. Our findings are therefore consistent with previous reports. This apparent discrepancy between serological and histopathological findings may reflect the well-recognized non-linear relationship between anti-tTG IgA titers and mucosal injury in CD. In addition, the patchy distribution of intestinal lesions may contribute to serology-histology discordance because biopsy samples may not fully capture the extent of mucosal involvement [317]. Although previous studies conducted in our country reported the classical presentation as the predominant phenotype (72%) of CD [18], the proportion of non-classical and subclinical cases has increased over time, likely owing to greater disease awareness, advances in serological testing, and improved recognition of the heterogeneous clinical spectrum of the disease [19]. Consistent with this trend, our study also observed an increase in the number of non-classical and subclinical cases over time. However, this increase was not statistically significant when the pandemic period was compared with the pre-pandemic period (p=0.084). During the COVID-19 pandemic, a decline in healthcare utilization by patients with non-classical disease, who often present with subtle symptoms, might have been expected [20]. Nevertheless, the proportion of non-classical and subclinical cases remained stable. This finding may be explained by our institution's role as a tertiary referral center and by the uninterrupted availability of outpatient services and serological testing throughout the pandemic. Although substantial evidence indicates that COVID-19-related restrictions, including quarantine measures and reduced physical activity, contributed to increased childhood obesity [21], we found no significant differences in body weight or BMI SDS between the pandemic and pre-pandemic groups. The absence of the anticipated weight gain in the pandemic cohort, despite the trend observed in the general pediatric population, may be attributable to prolonged gluten exposure resulting from delayed diagnosis and the associated malabsorption, which may have masked the obesogenic effects of the pandemic environment. This finding further supports the hypothesis that diagnostic delays during the pandemic prolonged the untreated disease course before diagnosis. The retrospective design and single-center setting of this study may limit the generalizability of our findings. The primary methodological limitation was the exclusion of four patients diagnosed without biopsy according to the current ESPGHAN guidelines because they exhibited very high serological titers (≥10×ULN) during the pandemic period [9]. This exclusion may have introduced selection bias by underrepresenting patients with the highest antibody titers in the pandemic cohort. However, one of the primary objectives of this study was to compare the severity of duodenal mucosal injury between the two periods. Because histopathological assessment was essential for evaluating this primary outcome, excluding patients without biopsy data was methodologically necessary. Moreover, despite the exclusion of these four patients, the pandemic group still demonstrated a significantly higher proportion of patients with antibody titers ≥10×ULN, reinforcing the robustness of our findings. Another limitation is the lack of direct measures of diagnostic delay, such as symptom duration before diagnosis, as well as quantitative indicators of healthcare access during the pandemic (e.g., referral or waiting times). Despite these limitations, this study contributes to the limited literature examining the clinical impact of the COVID-19 pandemic on pediatric CD. Unlike previous studies, the equal distribution of patients between the pandemic and pre-pandemic cohorts (57 vs. 57) enabled a more balanced comparison of outcomes between the two periods. Another major strength is the stratified analysis of serological results according to multiples of the ULN, which allowed us to evaluate not only seropositivity but also the magnitude of the serological response, particularly the increase in patients with antibody titers ≥10×ULN. Furthermore, in contrast to many previous studies, clinical presentation, serological findings, and histopathological severity, as assessed by the Modified Marsh classification, were comprehensively evaluated and compared across all patients. In conclusion, the COVID-19 pandemic was associated with an older age at diagnosis and a significantly greater serological burden among children with CD. However, despite the increase in serological burden, no corresponding increase in the severity of duodenal mucosal damage was observed compared with the pre-pandemic period. These findings suggest that pandemic-related disruptions primarily delayed diagnosis rather than accelerating histopathological progression and underscore the importance of maintaining uninterrupted diagnostic pathways for chronic diseases, even during periods of restricted access to healthcare services.